-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-765423 in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-765423 in Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-765423 in Pulmonary Fibrosis Drug Details: BI-765423 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nerandomilast in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nerandomilast in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nerandomilast in Idiopathic Pulmonary Fibrosis Drug Details: Nerandomilast (BI-1015550) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Nitrite in Pulmonary Tuberculosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sodium Nitrite in Pulmonary Tuberculosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sodium Nitrite in Pulmonary Tuberculosis Drug Details: Sodium nitrite (RESP301)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitiperstat in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitiperstat in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitiperstat in Pulmonary Arterial Hypertension Drug Details: Mitiperstat is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CMK-389 in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CMK-389 in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CMK-389 in Pulmonary Sarcoidosis Drug Details: CMK-389 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empagliflozin in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empagliflozin in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empagliflozin in Pulmonary Arterial Hypertension Drug Details: Empagliflozin (Jardiance, BI...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axatilimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axatilimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axatilimab in Idiopathic Pulmonary Fibrosis Drug Details: Axatilimab (SNDX-6352) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Infliximab Biosimilar in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Infliximab Biosimilar in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Infliximab Biosimilar in Pulmonary Sarcoidosis Drug Details: Infliximab biosimilar (XTMAB-16)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Genistein in Pulmonary Radiation Toxicity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Genistein in Pulmonary Radiation Toxicity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Genistein in Pulmonary Radiation Toxicity Drug Details: Genistein (BIO-300) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garadacimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Idiopathic Pulmonary Fibrosis Drug Details: Garadacimab (CSL-312) is...